康柏西普治疗视网膜分支静脉阻塞伴黄斑水肿的短期疗效观察
Short-Term Therapeutic Effects of Intravitreal Conbercept Injection for Macular Edema Secondary to Branch Retinal Vein Occlusion
DOI: 10.12677/HJO.2018.71001, PDF,   
作者: 赵芃芃, 秦 梅：蚌埠医学院第一附属医院眼科，安徽 蚌埠
关键词: 视网膜分支静脉阻塞；黄斑水肿；康柏西普；Branch Retinal Vein Occlusion； Macular Edema；Conbercept
摘要: 目的：观察玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿的短期临床疗效。方法：收集我院就诊诊断为BRVO伴有ME的患者14例，共计14只眼，采用“2 + PRN”治疗方案行玻璃体腔内注射康柏西普0.5 mg/0.05 mL，随诊3个月观察患者注药前后最佳矫正视力(BCVA)、黄斑中心厚度(CMT)的变化，同时观察患者眼压及并发症的出现。结果：14例(14眼) BRVO并发ME患者于随访末期有12例获得0.4 (LogMAR)及以下的最佳矫正视力，治疗前、随诊1周、1个月、3个月平均BCVA分别为0.70 ± 0.35、0.56 ± 0.35、0.45 ± 0.29、0.32 ± 0.23；术后1月与3月BCVA与术前相比较提高，差异有统计学意义(p < 0.05)。14例患者治疗前、随诊1周、1个月、3个月平均CMT分别为(454.57 ± 143.53) μm、(329.57 ± 92.53) μm、(281.00 ± 61.00) μm、(249.43 ± 65.17) μm，术后各随诊时间平均CMT较术前均降低，差异具有统计学意义(p < 0.05)。随诊各时间患者眼压均在正常范围内，与注药前比较差异不具有统计学意义(p > 0.05)。结论：玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞合并黄斑水肿短期内能改善视力和促进黄斑水肿的消退，安全有效。
Abstract: Objective: To assess the short-term clinical effects of intravitreal injection of conbercept for macular edema (ME) secondary to branch retinal vein occlusion (BRVO). Methods: A total of 14 patients (14 eyes) with macular edema following BRVO treated with “2 + PRN” intravitreal injection of conbercept 0.05 mg/0.05 mL were collected. The best corrected visual acuity (BCVA) and central macular thickness (CMT) were observed before treatment and 1 week, 1 month, 2 months, 3 months after treatment. Then, the changes in pre-treatment and post-treatment were compared, and the related complications were recorded. Results: Twelve of the 14 patients (14 eyes) compli-cated with ME achieved a BCVA of 0.4 (LogMAR) at the end of follow-up. The average BCVA of pre-treatment and 1 week, 1 months, 3 months follow-up were 0.70 ± 0.35, 0.56 ± 0.35, 0.45 ± 0.29 and 0.32 ± 0.23, respectively. The BCVA at 1 month and 3 months follow-up after operation was significantly higher than preoperative. The difference was statistically significant (p < 0.05). The average CMT of the 14 patients were (454.57 ± 143.53) μm, (329.57 ± 92.53) μm, (281.00 ± 61.00) μm and (249.43 ± 65.17) μm respectively at before treatment, 1 week, 1 month and 3 months fol-low-up. The average CMT of each follow-up time after operation was lower than that before opera-tion, the difference was statistically significant (p < 0.05). Intraocular pressure in patients with follow-up was within the normal range, compared with the injection before the difference was not statistically significant (p > 0.05). Conclusion: Intravitreal injection of conbercept in the treatment of BRVO with ME can improve visual acuity and promote the regression of macular edema in a short-time and is safe and effective.
文章引用：赵芃芃, 秦梅. 康柏西普治疗视网膜分支静脉阻塞伴黄斑水肿的短期疗效观察[J]. 眼科学, 2018, 7(1): 1-6. https://doi.org/10.12677/HJO.2018.71001

参考文献

[1] Rogers, S., Mcintosh, R.L., Cheung, N., et al. (2010) The Prevalence of Retinal Vein Occlusion: Pooled Data from Population Studies from the United States, Europe, Asia, and Australia. Ophthalmology, 117, 313-9 e1.
[2] Brown, D.M., Campochiaro, P.A., Bhisitkul, R.B., et al. (2011) Sustained Benefits from Ranibizumab for Macular Edema Following Branch Retinal Vein Occlusion: 12-Month Outcomes of a Phase III Study. Ophthalmology, 118, 1594-1602.
[Google Scholar] [CrossRef] [PubMed]
[3] Clark, W.L., Boyer, D.S., Heier, J.S., et al. (2016) Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. Ophthalmology, 123, 330-336.
[Google Scholar] [CrossRef] [PubMed]
[4] Tan, M.H., Mcallister, I.L., Gillies, M.E., et al. (2014) Randomized Controlled Trial of Intravitreal Ranibizumab versus Standard Grid Laser for Macular Edema Following Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 157, 237-247 e1.
[5] 白石. 不同方法治疗视网膜分支静脉阻塞继发黄斑水肿的疗效[J]. 国际眼科杂志, 2017, 17(4): 648-651.
[6] Arnarsson, A. and Stefansson, E. (2000) Laser Treatment and the Mechanism of Edema Reduction in Branch Retinal Vein Occlusion. Investigative Ophthalmology & Visual Science, 41, 877-879.
[7] Wang, Q., Li, T., Wu, Z., et al. (2013) Novel VEGF Decoy Receptor Fusion Protein Conbercept Targeting Multiple VEGF Isoforms Provide Remarkable Anti-Angiogenesis Effect in Vivo. PLoS One, 8, e70544.
[Google Scholar] [CrossRef] [PubMed]
[8] Dominguez, E., Raoul, W., Calippe, B., et al. (2015) Experimental Branch Retinal Vein Occlusion Induces Upstream Pericyte Loss and Vascular Destabilization. PLoS One, 10, e0132644.
[Google Scholar] [CrossRef] [PubMed]
[9] Christoffersen, N.L. and Larsen, M. (1999) Pathophysiology and Hemody-namics of Branch Retinal Vein Occlusion. Ophthalmology, 106, 2054-2062.
[Google Scholar] [CrossRef] 
[10] Karia, N. (2010) Retinal Vein Occlusion: Pathophysiology and Treatment Options. Clinical Ophthalmology, 4, 809-816.
[Google Scholar] [CrossRef] 
[11] Yau, J.W., Lee, P., Wong, T.Y., et al. (2008) Retinal Vein Occlusion: An Approach to Diagnosis, Systemic Risk Factors and Management. Internal Medicine Journal, 38, 904-910.
[Google Scholar] [CrossRef] [PubMed]
[12] Ehlers, J.P. and Fekrat, S. (2011) Retinal Vein Occlusion: Beyond the Acute Event. Survey of Ophthalmology, 56, 281-299.
[Google Scholar] [CrossRef] [PubMed]
[13] Noma, H., Funatsu, H., Mimura, T., et al. (2009) Vitreous Levels of Interleukin-6 and Vascular Endothelial Growth Factor in Macular Edema with Central Retinal Vein Occlusion. Ophthalmology, 116, 87-93.
[Google Scholar] [CrossRef] [PubMed]
[14] Bhisitkul, R.B., Campochiaro, P.A., Shapiro, H., et al. (2013) Predictive Value in Retinal Vein Occlusions of Early versus Late or Incomplete Ranibizumab Response Defined by Optical Coherence Tomography. Ophthalmology, 120, 1057-1063.
[Google Scholar] [CrossRef] [PubMed]
[15] Wroblewski, J.J., Wells 3rd, J.A. and Gonzales, C.R. (2010) Pegaptanib Sodium for Macular Edema Secondary to Branch Retinal Vein Occlusion. American Journal of Ophthalmology, 149, 147-154.
[Google Scholar] [CrossRef] [PubMed]
[16] Jaulim, A., Ahmed, B., Khanam, T., et al. (2013) Branch Retinal Vein Occlusion: Epidemiology, Pathogenesis, Risk Factors, Clinical Features, Diagnosis, and Complications. An Update of the Literature. Retina, 33, 901-910.
[Google Scholar] [CrossRef] 
[17] Zhang, M., Zhang, J., Yan, M. and Yu, D.C. (2008) Recombinant An-ti-Vascular Endothelial Growth Factor Fusion Protein Efficiently Suppresses Choridal Neovasularization in Monkeys. Molecular Vision, 14, 37-49.
[18] 宋莉, 沙翔垠, 郑瑜, 等. 康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿疗效分析[J]. 广东医学, 2017, 38(5): 778-780.
[19] 邢凯, 亢泽峰. 玻璃体腔内注射康柏西普治疗视网膜分支静脉阻塞继发黄斑水肿的疗效分析[J]. 山东大学耳鼻喉眼学报, 2016(1): 80-82.
[20] Noma, H., Funatsu, H., Harino, S., et al. (2010) Influence of Macular Microcirculation and Retinal Thickness on Visual Acuity in Patients with Branch Retinal Vein Occlusion and Macular Edema. Japanese Journal of Ophthalmology, 54, 430-434.
[Google Scholar] [CrossRef] [PubMed]
[21] Altunel, O., Duru, N., Goktas, A., et al. (2017) Evaluation of Foveal Photoreceptor Layer in Eyes with Macular Edema Associated with Branch Retinal Vein Occlusion after Ozurdex Treatment. International Ophthalmology, 37, 333-339.
[Google Scholar] [CrossRef] [PubMed]

为你推荐